Corporate | 26 June 2007 11:47
WILEX AG / Miscellaneous
Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.
----------------------------------------------------------------------
Patient recruitment started in clinical Phase II trial with WX-671 in
pancreatic cancer
Munich, 26 June 2007 The Munich-based biopharmaceutical company WILEX AG
(ISIN DE0006614720 / Frankfurt Stock Exchange / Prime Standard) has
randomized the first patient in its clinical Phase II pancreatic cancer
trial with the oral drug candidate WX-671 in combination with the
chemotherapeutic agent Gemcitabine (Gemzar®, Eli Lilly and Company,
Indianapolis, USA).
The study with 90 patients is being conducted in six countries. WILEX AG
had previously published details of the study design, having received the
clinical trial authorisation from the German authorities. This information,
the participating centres and the inclusion criteria will be available for
review on the company’s website www.wilex.com or www.clinicaltrials.gov.
First data from the trial is expected to be released in H1 2008.
Dr. Paul Bevan, Head of R&D and Member of the Executive Management at WILEX
AG remarked: 'We have commenced patient recruitment within the planned time
line und expect the trial to progress as scheduled. WX-671 is the first
substance of its kind worldwide to go into a clinical Phase II trial. This
is a major milestone in the development of anti-metastatic uPA-inhibitors.'
About the uPA programme
WILEX’s late stage multi-product portfolio includes two drug candidates,
WX-UK1 and WX-671, which are being developed as part of the Company’s
urokinase-type Plasminogen Activator programme ('uPA programme'). In this
programme WILEX is developing various compounds that inhibit the uPA
system. The uPA system plays a key role in the growth, spread and
metastasis of various malignant tumours. The Company expects that drug
candidates which emerge from the uPA programme may be used for the
treatment of patients with tumours such as breast, pancreatic, ovarian,
gastric and colon cancer.
WILEX successfully completed Phase I studies with WX-UK1 and WX-671. The
compounds were found to be safe and well tolerated. WX-671 can be
administered orally and is converted into WX-UK1 in the body. This
facilitates the long-term treatment of patients. Therefore, the Company
decided to investigate the efficacy of WX-671 in two Phase II trials. In
addition to the trial starting now the Company intends to conduct a Phase
II trial in which patients with metastatic breast cancer are to be treated
with WX-671 in combination with the chemotherapeutic agent Capecitabine
(Xeloda®, Hoffmann La Roche AG, Basle, Switzerland). The Company intends to
file for approval of this trial in 2007. After a positive outcome from
these Phase II trials, the Company intends to test WX-671 in different
types of cancer.
About WILEX
WILEX is a biopharmaceutical Company based in Munich founded in 1997 by a
team of physicians and oncologists from the Technical University of Munich.
WILEX is focused on the development of new cancer therapies based on
antibodies and small molecules. The therapeutic approach of WILEX targets
the prevention of growth, spread and the metastasis of malignant tumours
and the destruction of malignant tumours in the body. The late stage
multi-product portfolio includes both drug and medical product candidates
ranging from research to late stage clinical development. Currently the
following compounds are in clinical development: WX-G250 (development name:
RENCAREX®), WX-671, WX-UK1 and CA9-SCAN. The company’s strategy is to
develop WILEX into a commercially successful biopharmaceutical company with
a broad portfolio of new drugs and medical products for the treatment of
cancer. WILEX AG is listed at the Frankfurt Stock Exchange on the Official
Market Segment (Amtlicher Markt) / Prime Standard since November 13, 2006.
DGAP 26.06.2007
----------------------------------------------------------------------
Language: English
Issuer: WILEX AG
Grillparzerstr. 10
81675 München Deutschland
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info@wilex.com
Internet: www.wilex.com
ISIN: DE0006614720
WKN: 661472
Indices:
Listed: Amtlicher Markt in Frankfurt (Prime Standard); Freiverkehr in
Berlin-Bremen, Düsseldorf, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------------